Diphtheria Vaccine Market, by Vaccine Type (DTaP vaccine, DT vaccine, Tdap vaccine, and Td vaccine), by Age Group (Pediatrics and Adults), by End User (Hospitals, Clinics, and Vaccination Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Diphtheria is a serious infection caused by strains of bacteria called Corynebacterium diphtheriae that make a toxin. It is the toxin that can cause people to get sick. Diphtheria bacteria spread from person to person, usually through respiratory droplets, like from coughing or sneezing. The bacteria make a toxin that kills healthy tissues in the respiratory system. Within two to three days, the dead tissue forms a thick, gray coating that can build up in the throat or nose. Vaccines are available that help prevent diphtheria, an infection caused by Corynebacterium diphtheriae bacteria. There are four kinds of Vaccines used in the U.S. to protect against diphtheria, all of which also provide protection against other diseases such as tetanus, and pertussis. The Vaccines are as follow: Diphtheria and tetanus (DT) Vaccines, Diphtheria, tetanus, and pertussis (DTaP) Vaccines, Tetanus and diphtheria (Td) Vaccines, and Tetanus, diphtheria, and pertussis (Tdap) Vaccines.
Market Dynamics
Increase in the government and non-government organizations initiatives to develop diphtheria Vaccines and increase in the awareness among people regarding importance of diphtheria Vaccine is expected to drive the market growth. Moreover, increase in the prevalence of bacterial infection such as diphtheria and tetanus is expected to drive the market growth for the forecast period. For instance, according to an article published in national library of medicine in June 2021, there were around 2,243 cases of diphtheria in Middle East during the period between 2019 to 2020. Out of which, about 44% (978/2243, 43.6%) of the cases involved children aged 5 to 15 years. Respiratory tract infection was the predominant symptom (2044/2243, 91.1%), followed by pseudomembrane (1822/2243, 81.2%).
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook